CRISPR: Downside Bias

293
CRISPR extended its correction over the past few weeks, although the downside momentum has eased somewhat more recently. For now, we primarily expect a sell-off below the support at $30.02. Once a low is established there, the stock should move higher again. Alternatively, the shares could post another temporary rebound first. In that case, price would briefly break above the resistance at $61.76 to establish a new corrective high (probability: 34%).

免責聲明

這些資訊和出版物並非旨在提供,也不構成TradingView提供或認可的任何形式的財務、投資、交易或其他類型的建議或推薦。請閱讀使用條款以了解更多資訊。